Biotransformations of Anticancer Ruthenium(III) Complexes: An X‐Ray Absorption Spectroscopic Study
- 30 January 2013
- journal article
- research article
- Published by Wiley in Chemistry – A European Journal
- Vol. 19 (11) , 3609-3619
Abstract
An anti‐metastatic drug, NAMI‐A ((ImH)[RuIIICl4(Im)(dmso)]; Im=imidazole, dmso=S‐bound dimethylsulfoxide), and a cytotoxic drug, KP1019 ((IndH)[RuIIICl4(Ind)2]; Ind=indazole), are two Ru‐based anticancer drugs in human clinical trials. Their reactivities under biologically relevant conditions, including aqueous buffers, protein solutions or gels (e.g, albumin, transferrin and collagen), undiluted blood serum, cell‐culture medium and human liver (HepG2) cancer cells, were studied by Ru K‐edge X‐ray absorption spectroscopy (XAS). These XAS data were fitted from linear combinations of spectra of well‐characterised Ru compounds. The absence of XAS data from the parent drugs in these fits points to profound changes in the coordination environments of RuIII. The fits point to the presence of RuIV/III clusters and binding of RuIII to S‐donor groups, amine/imine and carboxylato groups of proteins. Cellular uptake of KP1019 is approximately 20‐fold higher than that of NAMI‐A under the same conditions, but it diminishes drastically after the decomposition of KP1019 in cell‐culture media, which indicate that the parent complex is taken in by cells through passive diffusion.Keywords
This publication has 61 references indexed in Scilit:
- Evaluation of drug toxicity with hepatocytes cultured in a micro-space cell culture systemJournal of Bioscience and Bioengineering, 2011
- Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339JBIC Journal of Biological Inorganic Chemistry, 2010
- Characterization of a Ruthenium(III)/NAMI‐A Adduct with Bovine Serum Albumin that Exhibits a High Anti‐Metastatic ActivityAngewandte Chemie International Edition, 2010
- Characterization of a Ruthenium(III)/NAMI‐A Adduct with Bovine Serum Albumin that Exhibits a High Anti‐Metastatic ActivityAngewandte Chemie, 2010
- Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPRJBIC Journal of Biological Inorganic Chemistry, 2009
- New trends for metal complexes with anticancer activityCurrent Opinion in Chemical Biology, 2008
- Probing the Formation Mechanism and Chemical States of Carbon-Supported Pt−Ru Nanoparticles by in Situ X-ray Absorption SpectroscopyThe Journal of Physical Chemistry B, 2006
- Solvolysis of the Tumor‐Inhibiting Ru(III)‐Complex trans‐Tetrachlorobis(Indazole)Ruthenate(III)Metal-Based Drugs, 2000
- Binding of ruthenium(III) anti-tumor drugs to human lactoferrin probed by high resolution X-ray crystallographic structure analysesJBIC Journal of Biological Inorganic Chemistry, 1996
- Refinement of the Crystal Structure of Ruthenium Dioxide.Acta Chemica Scandinavica, 1970